How Russell Index Reclassification Toward Growth Benchmarks Will Impact Inhibrx Biosciences (INBX) Investors
Inhibrx Biosciences (INBX) was reclassified from Russell value/defensive indices to growth/small-cap indices in late June 2026. This shift primarily affects the type of investors holding the stock and doesn't change the underlying business catalysts, which include regulatory progress, clinical trial execution, and balance sheet management. Investors should note the company's ongoing losses and negative equity, and some estimates suggest the stock may be trading beyond its fair value.
How Russell Index Reclassification Toward Growth Benchmarks Will Impact Inhibrx Biosciences (INBX) Investors
Inhibrx Biosciences (INBX) has been reclassified from Russell value and defensive indices to growth and small-cap benchmarks in late June 2026. This shift primarily affects the investor base rather than the core business drivers, with key catalysts remaining FDA decisions, clinical trial execution, and balance sheet management. The article suggests that despite the reclassification, the company is still early in its commercialization phase, faces ongoing losses, and might be trading beyond its estimated fair value.
(INBX) Price Dynamics and Execution-Aware Positioning
This article analyzes Inhibrx Biosciences Inc (NASDAQ: INBX) price dynamics, identifying a near-term neutral sentiment amidst mid and long-term strength. It highlights an exceptional 97.2:1 risk-reward setup, targeting a substantial gain with minimal risk. The analysis provides three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—along with multi-timeframe signal analysis to guide potential trades.
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) dropped from Russell 2000 Defensive Index
Inhibrx Biosciences, Inc. (NasdaqGS: INBX) has been removed from the Russell 2000 Defensive Index. This change is part of broader index adjustments, as the company was also added to other Russell indices like the Russell 2500 Growth and Russell 2000 Growth Benchmarks around the same date. The biopharmaceutical company is actively developing novel biologic therapeutic candidates, including ozekibart and INBRX-106.
Inhibrx Biosciences (INBX) Wins FDA Filing Acceptance, Is More Upside Already Priced In?
Inhibrx Biosciences (INBX) received FDA acceptance for its Biologics License Application for ozekibart, following positive Phase III data. Despite significant past share price momentum and an analyst target considerably higher than the current trading price, the company's financials show it is still a clinical-stage business with negative shareholders' equity and high-risk funding. Investors are cautioned to weigh the potential rewards against the inherent risks, including ongoing clinical development and financial vulnerabilities.
Inhibrx Biosciences, Inc.(NasdaqGS: INBX) added to Russell 3000E Growth Benchmark
Inhibrx Biosciences, Inc. (NasdaqGS: INBX) has been added to the Russell 3000E Growth Benchmark. This pharmaceutical company, which specializes in developing novel biologic therapeutic candidates, is actively advancing its clinical pipeline, including therapies like ozekibart (INBRX-109) and INBRX-106. The inclusion in this benchmark index highlights the company's growth trajectory and market recognition.
Inhibrx Biosciences, Inc.(NasdaqGS:INBX) dropped from Russell 2000 Value-Defensive Index
Inhibrx Biosciences, Inc. (NasdaqGS:INBX) has been removed from the Russell 2000 Value-Defensive Index. This change is part of broader Russell index reconfigurations, which also saw the company dropped from other defensive/value benchmarks and added to growth benchmarks like the Russell 2500 Growth and Russell 3000 Growth. Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic candidates.
Enterprise value to revenue forward of Inhibrx Biosciences, Inc. – NASDAQ:INBX
This article provides a financial snippet for Inhibrx Biosciences, Inc. (NASDAQ: INBX), focusing on its enterprise value to revenue forward metric. It details that the market is currently closed with no trades recorded for the company. The content appears to be a stub or a brief financial data point from a larger platform.
Price to sales forward of Inhibrx Biosciences, Inc. – NASDAQ:INBX
This article provides financial data, specifically the "Price to sales forward" for Inhibrx Biosciences, Inc. (NASDAQ: INBX). It notes that the market is closed with no trades recorded at the time of publication and lists the company on the Nasdaq Stock Market. The content is primarily a data point and lacks further narrative or analysis.
Inhibrx Biosciences (INBX) Short Interest & Short Float | Updated Jun 2026
Inhibrx Biosciences (INBX) reported a short interest of 3.30 million shares as of June 15, 2026, representing 27.52% of its public float, an increase of 3.79% from the previous report. The short interest ratio is 10.3 days to cover, indicating significant pessimism towards the stock. This report details the historical short interest data for INBX and defines key metrics like short interest, short float, and days to cover, comparing INBX's figures to competitors in the pharmaceutical sector.
INBX Forecast — Price Target — Prediction for 2027
This article provides a forecast for Inhibrx Biosciences, Inc. (INBX) stock, including analyst price targets, past performance, and basic financial information. It notes that analysts have a maximum estimate of $325.00 and a minimum estimate of $230.00 for INBX's future price. The stock has experienced a significant increase of 552.36% over the last year, despite recent weekly and monthly declines.
6 Biotech Stocks That Delivered Stunning Gains: INBX +700%, PVLA +500%, MBX +300%, ABSI +200% & More
This article highlights six biotech stocks (Inhibrx Biosciences, Palvella Therapeutics, MBX Biosciences, Protagonist Therapeutics, Absci Corp., and Belite Bio Inc) that have shown significant gains for long-term investors. It details the clinical developments, positive trial results, and future catalysts that have driven the impressive stock performance of each company, with gains ranging from over 100% to over 700% since their initial profile dates. The piece emphasizes the importance of patience and conviction in successful investing within the biotechnology sector.
The Bull Case For Inhibrx Biosciences (INBX) Could Change Following FDA BLA Acceptance For Ozekibart
Inhibrx Biosciences' investment narrative is shifting due to the FDA's acceptance of its Biologics License Application (BLA) for ozekibart to treat conventional chondrosarcoma. This approval sets a PDUFA decision date for April 14, 2027, converting a development-stage asset into a defined regulatory catalyst. While this strengthens the long-term outlook, the company still faces near-term challenges such as high cash burn and dependence on external financing.
(INBX) as a Liquidity Pulse for Institutional Tactics
This article analyzes Inhibrx Biosciences Inc (NASDAQ: INBX) using AI models to provide institutional trading strategies. Key findings indicate a positive near-term sentiment but a weak mid-term bias within a long-term strong context, with an exceptional 97.9:1 risk-reward setup. The analysis offers specific strategies for position trading, momentum breakout, and risk hedging, along with multi-timeframe signal analysis.
Inhibrx Biosciences (INBX) Stock Near Analyst Target After FDA Filing for Ozekibart
Inhibrx Biosciences (INBX) is gaining attention after the FDA accepted its Biologics License Application for ozekibart, used in treating chondrosarcoma, supported by positive trial data. While the stock has seen a significant one-year return, its 30-day performance shows a recent cool-down. The company's valuation is complex due to a high P/B ratio and negative equity, making its pipeline story and regulatory progress the primary focus for investors.
What is Inhibrx Biosciences, Inc. (INBX) stock_business overview_development history
Inhibrx Biosciences, Inc. (INBX) is a clinical-stage biopharmaceutical company specializing in novel biologic therapeutics for life-threatening conditions, particularly oncology and rare diseases, using its proprietary single-domain antibody (sdAb) platform. Following a spin-off from Inhibrx, Inc. in 2024, the company is focusing on assets like ozekibart (INBRX-109) and INBRX-106, with a planned BLA submission for ozekibart in Q2 2026. Analysts view the company as a "pure-play" oncology innovator with strong potential, despite the inherent risks of clinical-stage biotech.
Inhibrx Biosciences Inc (INBX) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Inhibrx Biosciences Inc (INBX)'s dividend and stock split history. It notes that the company has distributed $0.00 in dividends over the past five years and reports "No Data" for both historical dividend dates and stock splits. The piece highlights INBX's current stock price and market capitalization, offering a snapshot of its financial information.
Inhibrx Biosciences stock gains after FDA accepts drug filing By Investing.com
Inhibrx Biosciences Inc. (NASDAQ:INBX) shares rose 2.6% after the FDA accepted its drug application for ozekibart, a treatment for unresectable or metastatic conventional chondrosarcoma. The FDA set an April 14, 2027 goal date, with ozekibart poised to be the first FDA-approved treatment for this bone cancer and the company's first commercial product. The drug demonstrated significant efficacy in the ChonDRAgon study, reducing disease progression or death by 52% compared to placebo, with a manageable safety profile.
How FDA’s Ozekibart BLA Acceptance for Chondrosarcoma Could Shape Inhibrx Biosciences (INBX) Investors
The FDA has accepted Inhibrx Biosciences' Biologics License Application for ozekibart to treat chondrosarcoma, setting a PDUFA date of April 14, 2027. This acceptance strengthens the regulatory timeline but highlights the company's single-asset concentration and ongoing losses. Investors face execution and financing risks, with some analyses suggesting the stock may be overvalued despite potential significant upside.
FDA accepts Inhibrx (NASDAQ: INBX) BLA for first chondrosarcoma therapy
The FDA has accepted Inhibrx Biosciences' Biologics License Application (BLA) for ozekibart (INBRX-109) to treat unresectable or metastatic conventional chondrosarcoma, setting a PDUFA goal date of April 14, 2027. This marks a significant milestone as ozekibart could become the first FDA-approved systemic therapy for this aggressive bone cancer, which currently lacks approved options. The BLA is supported by the ChonDRAgon study, where ozekibart demonstrated a 52% reduction in disease progression or death risk and more than doubled median progression-free survival compared to placebo.
FDA accepts Inhibrx filing for rare bone cancer treatment By Investing.com
The FDA has accepted Inhibrx Biosciences' Biologics License Application for ozekibart, a treatment for unresectable or metastatic conventional chondrosarcoma, setting an April 14, 2027, goal date. Ozekibart, if approved, would be the first FDA-approved treatment for this rare bone cancer, backed by strong results from the ChonDRAgon study showing a significant reduction in disease progression or death. The company has also seen substantial investor interest and positive analyst ratings, with shares returning 533% over the past year.
Inhibrx Biosciences stock gains after FDA accepts drug filing By Investing.com
Inhibrx Biosciences Inc. (NASDAQ:INBX) shares rose after the FDA accepted its Biologics License Application for ozekibart to treat conventional chondrosarcoma, setting an April 14, 2027, goal date. This drug, if approved, would be the first FDA-approved treatment for this type of bone cancer and the company's first commercial product, supported by strong results from the ChonDRAgon study. The trial demonstrated a statistically significant median progression-free survival and a 52% reduction in disease progression risk for patients treated with ozekibart.
Inhibrx Announces U.S. FDA Acceptance of BLA for Ozekibart in Patients with Conventional Chondrosarcoma
Inhibrx Biosciences, Inc. announced that the U.S. FDA has accepted its Biologics License Application (BLA) for ozekibart (INBRX-109) to treat patients with unresectable or metastatic conventional chondrosarcoma. The FDA set a PDUFA goal date of April 14, 2027, with no identified filing review issues. This represents a significant milestone as ozekibart, if approved, would be the first FDA-approved treatment for this aggressive bone cancer, based on positive results from the ChonDRAgon study showing a statistically significant improvement in progression-free survival.
Inhibrx Biosciences (INBX) director granted 15,000 stock options at $95.22
Inhibrx Biosciences director Douglas Forsyth was granted stock options for 15,000 shares of common stock at an exercise price of $95.22 per share. These options, which are a form of equity compensation, will become fully exercisable on June 3, 2027, provided Forsyth continues his service, and will expire on June 3, 2036. This transaction reflects a routine grant and not an open-market purchase or sale.
Inhibrx Biosciences (INBX) director granted 15,000 stock options at $95.22
Inhibrx Biosciences director Kimberly Manhard was granted 15,000 stock options at an exercise price of $95.22 per share. These options are part of her compensation, will be fully exercisable on June 3, 2027, contingent on her continued service, and do not represent an open-market transaction. Following this grant, she holds 15,000 stock options.
Inhibrx Biosciences (INBX) director receives 15,000 stock options at $95.22 strike
Inhibrx Biosciences director Kristiina Vuori, MD, was granted 15,000 stock options with an exercise price of $95.22 per share. These options, which vest fully on June 3, 2027, and expire on June 3, 2036, are a compensation-related award rather than an open-market purchase, aligning her incentives with the company's long-term performance. The transaction was reported in a Form 4 SEC filing, detailing the terms and conditions of the equity award.
Inhibrx Biosciences (INBX) director receives grant of 15,000 stock options
Inhibrx Biosciences director Jon Faiz Kayyem was granted 15,000 stock options with an exercise price of $95.22 per share. These options become fully exercisable on June 3, 2027, contingent on his continued service, and expire on June 3, 2036. This is a compensation-related grant and not an open-market transaction, indicating a neutral signaling value about the director's view of the stock.
Inhibrx Biosciences (NASDAQ: INBX) investors approve directors and BDO
Inhibrx Biosciences, Inc. (NASDAQ: INBX) held its 2026 Annual Meeting of Stockholders, where investors approved the election of two Class II directors, Douglas G. Forsyth and Kimberly Manhard, to serve until the 2029 Annual Meeting. Shareholders also ratified the appointment of BDO USA, P.C. as the independent registered public accounting firm for the fiscal year ending December 31, 2026. A significant quorum of approximately 79% of eligible shares was present at the virtual meeting.
Stifel Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $325
Stifel has reiterated its Buy rating for Inhibrx Biosciences (INBX.US) and maintained its target price of $325. This indicates a continued positive outlook from the analyst firm on the company's stock performance.
(INBX) Movement as an Input in Quant Signal Sets
This article analyzes Inhibrx Biosciences Inc (NASDAQ: INBX) using quantitative signals. It identifies weak near and mid-term sentiment but a strong long-term outlook, with a significant risk-reward short setup. The report provides detailed trading strategies (position, momentum, risk hedging) and multi-timeframe signal analysis, highlighting key support and resistance levels.
How Positive INBRX-106 Phase 2 Data And Narrower Losses At Inhibrx Biosciences (INBX) Have Changed Its Investment Story
Inhibrx Biosciences (INBX) reported narrower first-quarter losses and positive interim Phase 2 data for INBRX-106, a drug showing improved objective response rates in head and neck cancer when combined with pembrolizumab. This strengthens the near-term investment narrative by highlighting the efficacy of their OX40 platform, although the company still faces financial risks as a loss-making, early-stage biotech with high execution risk for future trials. The stock's recent performance suggests market expectations have already shifted, though its estimated value remains a point of debate.
Inhibrx Biosciences Hits Day Low of $99.70 Amid Price Pressure
Inhibrx Biosciences, Inc. experienced a significant stock decline, dropping 8.37% and hitting a day low of $99.70. Despite this setback, the company has demonstrated strong annual growth of 707.97%. Financially, Inhibrx Biosciences reported net sales of $1.3 million but is still dealing with a substantial net loss and no dividend yield.
Inhibrx Biosciences (INBX) price target increased by 66.67% to 255.00
The price target for Inhibrx Biosciences (INBX) has been increased by 66.67% to 255.00. This article is a brief news update focusing solely on this change in price target for the company.
A Look At Inhibrx Biosciences (INBX) Valuation After HexAgon Phase 2 Data And Phase 3 Plans
Inhibrx Biosciences (INBX) is garnering investor attention following positive interim Phase 2 HexAgon data for its cancer treatment INBRX-106 and recent Q1 earnings. Despite a significant stock price increase and a high P/B ratio (76.4x) due to negative equity, the stock's valuation remains a point of discussion, with analysts having a higher price target than the current close. The company's future hinges on upcoming HexAgon data and managing ongoing losses of approximately $130.2 million.
TRANSCENTA-B: Positive Interim Data from ozekibart Mid-stage Study; Greater China Plan Under Evaluation
TRANSCENTA-B (06628.HK) announced positive interim data from its partner Inhibrx Biosciences' Phase 1/2 study of ozekibart in colorectal cancer. Inhibrx also submitted a Biologics License Application (BLA) for ozekibart in conventional chondrosarcoma to the FDA. Transcenta holds exclusive rights for ozekibart in Greater China and is evaluating its plans in the region based on these developments.
Liquidity Mapping Around (INBX) Price Events
This article provides a liquidity mapping analysis for Inhibrx Biosciences Inc Com (NASDAQ: INBX), indicating weak near and mid-term sentiment but a strong long-term outlook. It presents three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis highlights a significant 95.7:1 risk-reward setup for a potential 27.3% gain.
Inhibrx Biosciences' INBRX-106 combo tops KEYTRUDA alone in phase 2 cancer study
Inhibrx Biosciences announced positive results from a Phase 2 study where its INBRX-106 in combination with KEYTRUDA showed superior overall response rates compared to KEYTRUDA alone in patients with advanced solid tumors. The combination therapy achieved a higher overall response rate, particularly in PD-L1 positive patients. These findings suggest a promising new treatment approach for specific cancer types, especially those expressing PD-L1.
Inhibrx Biosciences Reports Strong Phase 2 Response Data For INBRX 106 And Pembrolizumab Combination In Head And Neck Cancer
Inhibrx Biosciences announced positive interim Phase 2 results from the HexAgon study, showing a 44% confirmed objective response rate for INBRX-106 plus pembrolizumab in patients with Head and Neck Squamous Cell Carcinoma, a 22.6% absolute increase over pembrolizumab alone. The combination demonstrated deeper tumor reductions, significant T-cell expansion, and a manageable safety profile. These findings suggest INBRX-106's potential to enhance immunotherapy efficacy and the company plans further studies in various indications, including non-small cell lung cancer.
LifeSci Capital Maintains Inhibrx Biosciences(INBX.US) With Buy Rating, Maintains Target Price $230
LifeSci Capital analyst Oliver McCammon has reiterated a "Buy" rating for Inhibrx Biosciences (INBX.US) and maintained a target price of $230. According to TipRanks data, the analyst has a 64.9% success rate and an average return of 88.0% over the past year. This report highlights the analyst's continued positive outlook on the company's stock.
Viking Global holds 1.46M shares in Inhibrx (INBX); amendment removes one reporter
Viking Global has reported its beneficial ownership in Inhibrx (INBX) through an amended SCHEDULE 13G/A filing, indicating holdings of 1,461,633 shares, which represent 9.99% of the company's outstanding common stock. The amendment also noted the removal of David C. Ott as a reporting person due to his retirement, effective March 31, 2026. The filing details how ownership is allocated among various Viking Global entities and explains a "Blocker" mechanism for warrants that prevents ownership from exceeding 9.99% (with a potential increase to 19.99% after notice).
Perceptive (INBX) reports a 9.99% stake in INHIBRx via Schedule 13G/A
Perceptive Advisors LLC, along with Joseph Edelman and Perceptive Life Sciences Master Fund, Ltd., has filed an amended Schedule 13G/A, reporting a shared beneficial ownership of 9.99% in INHIBRx Biosciences (INBX). This stake, totaling 1,461,105 shares, is based on 14,607,286 outstanding shares as of April 7, 2026, and includes pre-funded warrants subject to a beneficial ownership limitation. The filing details that the Master Fund directly holds common stock and pre-funded warrants, with Perceptive Advisors and Joseph Edelman identified as beneficial owners by attribution.
INBX SWOT Analysis: Financial Challenges and Promising Pipeline Revealed in 10-Q Filing
This article provides a SWOT analysis of Inhibrx Biosciences Inc (INBX) based on its latest 10-Q filing. It highlights the company's strong pipeline of therapeutic candidates and focus on R&D as strengths, while pointing out significant financial weaknesses, including ongoing operating losses and low profitability. Opportunities exist in clinical trial advancements and strategic partnerships, though threats include intense competition and reliance on external funding.
Inhibrx Reports First Quarter 2026 Financial Results
Inhibrx Biosciences, Inc. reported its financial results for the first quarter of 2026, highlighting a net loss of $33.4 million, an improvement from the $43.3 million loss in Q1 2025. The company also announced key clinical trial updates for INBRX-106 and ozekibart (INBRX-109), including planned data announcements and regulatory interactions with the FDA for potential accelerated pathways. Cash and cash equivalents increased to $161.7 million due to additional loan proceeds.
Inhibrx Biosciences (INBX) cuts Q1 2026 loss, boosts cash but ups debt
Inhibrx Biosciences reported a narrower net loss of $33.4 million in Q1 2026, down from $43.3 million in Q1 2025, primarily due to reduced R&D expenses. The company's cash and cash equivalents increased to $161.7 million, bolstered by an additional $75.0 million in loan proceeds, which also raised long-term debt to $175.0 million and resulted in a stockholders' deficit. Inhibrx advanced its clinical pipeline with updated interim data for INBRX-106 and ozekibart, and submitted a Biologics License Application for ozekibart in conventional chondrosarcoma.
Inhibrx Inc stock (US45720L1070): Biotech firm in Virtus ETF holdings
Inhibrx Inc (INBX), a clinical-stage biotechnology firm, is a top holding in the Virtus Biotech Clinical Trials ETF (BBC), signaling its importance in clinical innovation for US investors. The company specializes in developing precision protein therapeutics for oncology, immunology, and rare diseases, with key assets like INBRX-109 in Phase 1 trials. Its presence in the Nasdaq-listed ETF offers US investors direct access to its growth potential tied to trial outcomes and partnerships.
Inhibrx Biosciences (INBX) Announces Positive Interim Results From Phase 2 Portion of HexAgon Study
Inhibrx Biosciences (NASDAQ: INBX) announced positive interim results from the Phase 2 portion of its HexAgon study for INBRX-106 in combination with pembrolizumab for Head and Neck Squamous Cell Carcinoma. The study achieved a 44.0% confirmed Objective Response Rate, with most responding patients showing significant tumor reductions and three achieving complete radiographic responses. Stifel subsequently raised its price target on INBX to $300 from $150, maintaining a 'Buy' rating.
Inhibrx Biosciences Reports Strong Phase 2 Response Data For INBRX 106 And Pembrolizumab Combination In Head And Neck Cancer
Inhibrx Biosciences announced positive interim Phase 2 results for INBRX-106 combined with pembrolizumab in head and neck cancer, showing a 44% confirmed objective response rate and deeper tumor reductions compared to pembrolizumab alone. The study demonstrated robust T-cell expansion and a manageable safety profile. The company plans to advance to Phase 3 and explore broader indications for OX40 agonism.
Inhibrx Biosciences Reports Strong Phase 2 Response Data For INBRX 106 And Pembrolizumab Combination In Head And Neck Cancer
Inhibrx Biosciences reported positive interim results from its Phase 2 HexAgon study for INBRX-106 combined with pembrolizumab in head and neck cancer, showing a 44% confirmed objective response rate and deeper tumor reductions. This combination demonstrated a 22.6% absolute increase in confirmed responses compared to pembrolizumab alone, along with robust T-cell expansion and a manageable safety profile. The company plans to advance to Phase 3 in Q3 2026 and explore INBRX-106 in broader indications like non-small cell lung cancer.
Inhibrx Biosciences reports positive Ph2 trial data, stock gains
Inhibrx Biosciences' shares rose in premarket trading after the company announced positive interim results from the Phase 2 portion of its HexAgon study. The trial, evaluating INBRX-106 in combination with pembrolizumab for Head and Neck Squamous Cell Carcinoma, showed a significantly higher Objective Response Rate compared to pembrolizumab alone. The combination also demonstrated a manageable safety profile, with progression-free survival data expected in Q4 2026.
Inhibrx Biosciences (INBX) Stock Jumps 17% on Positive Cancer Trial Results
Inhibrx Biosciences (INBX) saw its stock jump 17% following positive preliminary Phase 2 HexAgon study results for its head-and-neck cancer drug, INBRX-106. The drug, when combined with pembrolizumab, achieved a 44% objective response rate compared to 21.4% for pembrolizumab alone, along with significant T-cell proliferation and a manageable safety profile. Phase 3 of the trial is expected to begin in Q3 2026, with progression-free survival data anticipated in Q4 2026.
